Wuhan Hiteck Biological Pharma Co Ltd
300683
Company Profile
Business description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Contact
Hite Science and Technology Park
Wuhan Economic and Technological Development Zone
Hubei Province
Wuhan430056
CHNT: +86 2784599931
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
958
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |